STAT3 is known to be the master regulator of mesenchymal differentiation in glioma cells (Carro et al., 2010), and, hence, this provides meaningful insights into the evolution of G-CIMP-low recurrent cells along the aberrant mesenchymal lineage transformation and into the unfavorable patient outcomes because these tumors can emerge as secondary GBMs. Here, STAT3 is linked to glioma.